PA
LRCX icon

PharVision Advisers’s Lam Research LRCX Stock Holding History

PharVision Advisers’s Portfolio LRCX Stock Details LRCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,116
Closed -$283K – 870
2025
Q3 		$283K Buy
+2,116
New +$224K 0.16% 261
2025
Q2 		– Sell
-3,002
Closed -$218K – 365
2025
Q1 		$218K Sell
3,002
-1,806
-38% -$142K 0.3% 173
2024
Q4 		$347K Buy
+4,808
New +$365K 0.29% 107

Other funds holding LRCX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PharVision Advisers's LRCX Position: Q4 2025 in Review

PharVision Advisers sold out of Lam Research (LRCX) in Q4 2025, closing a stake of 2,116 shares — an estimated $283K sold.

PharVision Advisers first reported a position in LRCX in Q4 2024 and held it in 3 quarters. The position peaked at $347K in Q4 2024. 2,395 funds tracked by Wall St. Rank hold LRCX as of Q4 2025.

  • PharVision Advisers reported no remaining Lam Research position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 2,116 Lam Research shares in Q4 2025, an estimated $283K.
  • PharVision Advisers first reported a position in Lam Research in Q4 2024 and held it in 3 quarters.
  • PharVision Advisers's Lam Research position peaked at $347K in Q4 2024.
  • 2,395 funds tracked by Wall St. Rank held Lam Research as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.